Malaysia Truly Asia AEROMEET returns on virtual platform

PUTRAJAYA, Nov 16 — Malaysia Truly Asia AEROMEET, a platform where tourism industry players from the Americas, Europe and Oceania (AERO) regions engage in business-to-business (B2B) sessions, has returned this year after a hiatus since 2014.Organised …

N.Sembilan gov’t allocates RM41.2 million to DID, MARRIS this year – MB

SEREMBAN, Nov 16 — The Negeri Sembilan government has allocated RM 41.2 million to the state Department of Irrigation and Drainage (DID) for development and maintenance works this year, said Menteri Besar, Datuk Seri Aminuddin Harun.He said that, of …

More women in tourism sector lose job due to COVID-19 pandemic – Nancy

KUALA LUMPUR, Nov 16 — More women workers in the tourism sector have been affected by job loss compared to men globally, as more women were involved in the tourism-related industries hardest hit by the COVID-19 crisis, according to the International L…

MAHB free to form joint ventures for airport expansion project

KUALA LUMPUR, Nov 16 — The Transport Ministry (MoT) does not prohibit Malaysia Airports Holdings Bhd (MAHB) from forming joint ventures with private entities to carry out airport expansion projects.However, MAHB had chosen to postpone the implementat…

Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment

CALGARY, Alberta, Nov. 15, 2021 (GLOBE NEWSWIRE) — Zenith Capital Corp. (“Zenith” or the “Company”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics”), a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara Biopharma Co., Ltd. (“Newsoara”) for Zenith Epigenetics’ lead compound, ZEN-3694, in Asia excluding Middle East and North Africa […]

Junshi Biosciences and Coherus Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer

SHANGHAI, China and REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today that the United States Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (ODD) for toripalimab for the treatment of esophageal cancer. Orphan […]

CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company’s board of directors. “As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel […]